We are offering peptide therapy in partnership with Cellular Peptides, a U.S.-based, research-driven provider whose protocols are supported through ongoing Institutional Review Board (IRB) research
The purinergic receptor family, including P2Y 12 (involved in microglial chemotaxis) and P2X 7 (which activates the inflammasome), is also being actively investigated as a potential pharmacological target [488, 489]
CormeraisYGiulianoSLeFlochRFrontBDurivaultJTambutteEet al
In this regard, topical triple combination therapy containing hydroquinone 4%, tretinoin 0.05%, and fluocinolone 0.01% have received the Food and Drug Administration (FDA) approval in melasma management
The contrast with 2015 is stark
doi:10.1016/S0021-9258(18)64790-8